This simple, isocratic, normal-phase liquid-chromatographic method concurrently measures flecainide acetate and propranolol in 100 1L of serum within 8 mm. The chromatographic system consists of a Waters "Resolve" column packed with 5-pm silica spheres and a mobile phase of ammonium sulfate (10 mmol/L, pH 6.8)/methanol (22/78 by vol), pumped at 0.9 mL/min and monitored by a fluorometer 
acetate, is a relatively new antiarrhythmic agentused to suppressventricular arrhythmias. Suppliedas "Tambocor" by 3M Riker,St.Paul,MN 55144, thedrug is clinically effective on oral administration.
It has
a relatively long half-life, ranging from 12 to 27 h (mean -20 h) (1, 2). Its optimal effectis recognized when its "trough" concentration(i.e., the concentration measured justbeforea next dose)ismaintained at200-1000 gfL (2, 3). On the basis ofclinical experience, Nappi and Anderson (1) suggesteda therapeuticrange of -400-1000 gfL for patients withoutadvanced renalfailure or congestive heart failure. Toxiceffects produced by concentrations ofthe drug in plasma exceeding this includenew or worsened congestive heart failure, exacerbated arrhythmias, and slowed cardiac conduction, as well as dizziness and visual disturbances (1, 2).
During the initial investigational studiesin the United States, concentrations of fiecamide in plasma were measured by gas-liquid chromatography with electron-capture detection(1). Since then, various HPLC procedureshave been developed(4-6). Unfortunately, these lackthe sensitivity todetect low concentrations offlecainide unless larger samples are analyzed. We describe here a simple,sensitive HPLC procedure for the concurrentmeasurement of propranolol and fiecainide acetate. With a slight change in mobile phase,the system can alsobe used toquantifyanuodarone and its metabolite (9). The ability toquantifymore than one drug concurrently and to combine methods with similaroperatingconditions intoone system enablesmaximum utilization ofexpensive equipment,minimizes operation cost, and expedites results. Analytical variables. For the analytical-recovery studies we added both drugs to water and to drug-free plasma to produce concentrations of flecainide at 100,500, and 1000 tg/Land propranolol at50 and 100 pg/L and extracted these samples as described above.We alsoprepared corresponding dilutions of each drug in methanol, but at half the concentrations just listed, to allow for the dilution factor of the reconstitution step.All reconstituted extracted and unextracted samples were injected into the column in triplicate. We made manual injections intoa 50-4 sampling loop,to ensure consistent injection volumes. To determine absolute recovery, we compared the peak areas of the extracted samples with thoseofthe unextracted methanol dilutions. To determine analytical recovery,
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we first calculated the ratio of each drug peak to that of the internal standard. After determining theseratios fortheserum-based samples, we then compared them with the corresponding ratios for the aqueous samples.
As the comparison method we used the Abbott fluorescence polarization iminunoassay protocol for flecainide analysis with the TDx (Abbott Laboratories, North Chicago, IL 60064) as described in the manufacturer's manual.
Results and Discussion
Propranolol, flecaimde acetate, and the internal standard are well resolvedwithin an 8-mm run time as shown in Figures1 and 2.Retentiontimesare 5.4,6.3, and 7.1mm for propranolol, flecaimdeacetate, and internalstandard,respectively.
In the liquid-extraction procedure, we saw no differences inanalytical recoverybetween the aqueous and the serumbased standards. The absoluterecovery ofeitherdrug from serum, as compared with an appropriately diluted unextracted methanol solution, was 85%. When we evaluateda We preferredthe liquid-extraction procedure because of its improved recovery,simplertechnique,and lesser cost. To determinemethod correlation between HPLC and TDx results forflecainide, we began with a calibration crossover study. In-house-prepared, plasma-based calibrators were compared with commercial TDx flecainide calibrators. TDx calibrators assayed by the HPLC method showed the relationship: y (measured) = 0.90x (prepared) + 9 zg/L (R2 = 0.999, n = 6). When the HPLC calibrators (25, 100,600 , and 1000 tg/L)were assayedby the TDx, the correlation was:y (measured)= 1.lx(prepared) (R2 = 0.999,n = 4). There doesappear tobe some variability inthecalibrators from site tosite, as shown by the differences inslopes. Some ofthisvariation may be attributable to the use ofseasoned vs unseasoned glassware in preparing calibrators. We have observed that dilutions prepared in unseasoned glassware produce much more erratic and slightly lower results than identical dilutions prepared at the same time in seasoned flasks. The flecainide assay appears to be more affected by thisthan the propranolol assay,but thisvariability is not sufficient to account completelyforthe difference between thetwo setsofcalibrators. In any casewe suggestthe use of the pre-seasoning technique, because we find thatproduces veryconsistent and (we believe) accuratecalibrator concen-
trations.
The column used in this method has proven to be very durable. We routinely can make more than 1000 injections before the column starts to deteriorate. We use 2 L of mobile phase, recycling it during the analysis. After about a month (or about 200-300 injections) the chromatograms start to show a trough immediately after the internal standard. We usually prepare fresh mobile phase at this time, because the trough makes it more difficult for the data system to integrate peak area accurately. Once or twice during the useful life ofa column, we change the inlet column ifiter to correct for a slight increase of pressure in the system. We also use this same column and pump for amiodarone analysis by simply equilibrating the column for 15 mm in an amiodarone mobile phase that is very similar to that of the flecainide assay (9). size, and its adaptability to a currently operating liquidchromatographic system provides a cost-effective way of increasing therapeutic drug monitoring services with minimal additional expense.
